Results 71 to 80 of about 1,261,208 (309)

Durvalumab supplementation for non-small-cell lung cancer: a meta-analysis study

Journal of Cardiothoracic Surgery
Background Durvalumab supplementation may have some potential in improving the efficacy in patients with non-small-cell lung cancer (NSCLC), and this meta-analysis aims to explore the impact of durvalumab supplementation on efficacy for NSCLC.
Chengchen Wang, Hongyi Fu, Feng Wang
doaj   +1 more source

The addition of bevacizumab to standard chemotherapy in breast cancer : which patient benefits the most? [PDF]

, 2013
Bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor, is an effective and well-tolerated treatment option for patients with breast cancer.
Cocquyt, Veronique, Denys, Hannelore, KRUSE, VIBEKE, Van Belle, Simon, Van den Broecke, Rudy   +4 more
core   +2 more sources

Prevalence and Trajectory of Household Material Hardship Among Children With Advanced Cancer

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background/Objectives Families of children with advanced cancer living in poverty experience inferior outcomes including poor parent mental health and worse child quality of life. Household material hardship (HMH: food, housing, transportation, and/or utility insecurity) is a modifiable poverty exposure—and potential intervention target—that ...
Sarah Wright, Morgan A. Paul, Selena Murcia Mendez, Emily Jones, Lucille Lokko, Chelsea Heneghan, Nicholas Purol, Morgan Arnold, Rahela Aziz‐Bose, Colleen A. Kelly, Sandi L. Pruitt, Joanne Wolfe, Kira Bona, Puja J. Umaretiya   +13 more
wiley   +1 more source

Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study

BMC Cancer, 2020
Background The purpose of this study was to assess the efficacy and safety of cisplatin-based chemotherapy with or without bevacizumab (BEV) in Chinese women with advanced cervical cancer (ACC).
Xiaoli He, Jun Liu, Li Xiao, Mingdong Zhao, Tingting Su, Tiejian Liu, Guowei Han, Yue Wang   +7 more
doaj   +1 more source

Cost-effectiveness of [18F] fluoroethyl-L-tyrosine for temozolomide therapy assessment in patients with glioblastoma [PDF]

, 2019
Background and Purpose: Glioblastomas are the most aggressive of all gliomas. The prognosis of these gliomas, which are classified as grade IV tumors by the World Health Organization (WHO), is poor.
Baguet, Tristan, De Vos, Filip, Goethals, Ingeborg, Verhoeven, Jeroen   +3 more
core   +1 more source

Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival [PDF]

JNCI: Journal of the National Cancer Institute, 2009
Whether progression-free survival (PFS) or overall survival (OS) is the more appropriate endpoint in clinical trials of metastatic cancer is controversial. In some disease and treatment settings, an improvement in PFS does not result in an improved OS.We partitioned OS into two parts and expressed it as the sum of PFS and survival postprogression (SPP).
Kristine R, Broglio, Donald A, Berry
openaire   +2 more sources

The Fate (Outcome) of Clinically Apparent Single Lesion and Oligofocal Nephroblastomatosis Treated According to SIOP/GPOH Protocols for Wilms Tumor

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background The management of clinically apparent single lesions or oligofocal nephroblastomatosis, a facultative precursor of nephroblastoma, remains debated. Methods We retrospectively analyzed 37 patients with clinically apparent single or oligofocal nephroblastomatosis (two to three lesions per kidney) among 2347 patients registered between
Nils Welter, Jens‐Peter Schenk, Jenny Wegert, Manfred Gessler, Leo Kager, Stefan Wagenpfeil, Marina Müller, Jean‐Michel Wolff, Joerg Fuchs, Steven W. Warmann, Clemens‐Magnus Meier, Jochen Hubertus, Christian Rübe, Christian Vokuhl, Patrick Melchior, Lena Tschirner, Norbert Graf, Rhoikos Furtwängler   +17 more
wiley   +1 more source

Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial

Current Oncology
Background: A single measurement or a summary of a limited number of measurements of CA125 was considered in the prediction of clinical outcomes for patients with ovarian cancer.
Chang Yin, Josee-Lyne Ethier, Mark S. Carey, Dongsheng Tu, Xueying Zheng   +4 more
doaj   +1 more source

Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study

BMC Cancer, 2023
Purpose The aim of the present study was to assess the efficacy and safety of transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab (hereafter, TACE-Atez/Bev) in the treatment of advanced hepatocellular carcinoma (HCC ...
Fei Cao, Changsheng Shi, Guofu Zhang, Jun Luo, Jiaping Zheng, Weiyuan Hao   +5 more
doaj   +1 more source

Chordoma. Clinical characteristics, management and prognosis of a case series of 25 patients [PDF]

, 2010
Background: Adequate surgery still remains the only curative treatment of chordoma. Interesting clinical data on advanced disease with molecularly targeted therapies were reported.Methods: We described the clinical outcome of a series of chordoma ...
Virginia Ferraresi, Carmen Nuzzo, Carmine Zoccali, Ferdinando Marandino, Antonello Vidiri, Nicola Salducca, Massimo Zeuli, Diana Giannarelli, Francesco Cognetti, Roberto Biagini, A Jemal, R Chugh, CE Peña, JM Mirra, NL Higinbotham, C Catton, PW Chambers, S Boriani, F Tzortzidis, D Baratti, D Schulz-Ertner, DC Weber, GF Fleming, E Tamborini, S Stacchiotti, H Hof, K Schönegger, ZL Gokaslan, HY Zhang, P Bergh, KL Foweraker, PA Forsyth, BJ Cummings, P Gabriele, GC Feigl, HD Suit, M Austin-Seymour, M Austin-Seymour, G Noël, R Chugh, PG Scimeca, A Azzarelli, PG Casali, PG Casali, PM Weinberger, S Stacchiotti   +45 more
core   +1 more source